Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3‐month observational, longitudinal, cohort, multicenter, Italian real‐life study
-
- Fabrizio Vernieri
- Headache and Neurosonology Unit Campus Bio‐Medico University Hospital Rome Italy
-
- Claudia Altamura
- Headache and Neurosonology Unit Campus Bio‐Medico University Hospital Rome Italy
-
- Nicoletta Brunelli
- Headache and Neurosonology Unit Campus Bio‐Medico University Hospital Rome Italy
-
- Carmelina Maria Costa
- Headache and Neurosonology Unit Campus Bio‐Medico University Hospital Rome Italy
-
- Cinzia Aurilia
- Headache and Pain Unit San Raffaele Pisana, Scientific Institute for Research and Health Care Rome Italy
-
- Gabriella Egeo
- Headache and Pain Unit San Raffaele Pisana, Scientific Institute for Research and Health Care Rome Italy
-
- Luisa Fofi
- Headache and Pain Unit San Raffaele Pisana, Scientific Institute for Research and Health Care Rome Italy
-
- Valentina Favoni
- Bologna Institute of Neurological Sciences, Scientific Institute for Research and Health Care Bologna Italy
-
- Carlo Lovati
- Neurology Unit Headache Center L. Sacco University Hospital Milan Italy
-
- Davide Bertuzzo
- Neurology and Stroke Unit Asti Hospital Asti Italy
-
- Florindo d’Onofrio
- Neurology Unit San Giuseppe Moscati Hospital Avellino Italy
-
- Alberto Doretti
- Department of Neurology Stroke Unit and Laboratory of Neuroscience Italian Auxological Institute Scientific Institute for Research and Health Care Milan Italy
-
- Paola Di Fiore
- Headache Center, Neurology and Stroke Unit S. Carlo Borromeo Hospital Milan Italy
-
- Cinzia Finocchi
- San Martino Polyclinic Hospital, Scientific Institute for Research and Health Care Genoa Italy
-
- Francesca Schiano Di Cola
- Neurology Unit Department of Clinical and Experimental Sciences University of Brescia Brescia Italy
-
- Angelo Ranieri
- Headache Center, Neurology and Stroke Unit A. Cardarelli Hospital Naples Italy
-
- Bruno Colombo
- San Raffaele Hospital, Scientific Institute for Research and Health Care Vita‐Salute San Raffaele University Milan Italy
-
- Francesco Bono
- Center for Headache and Intracranial Pressure Disorders Neurology Unit, Mater Domini University Hospital Catanzaro Italy
-
- Maria Albanese
- Headache Center Neurology Unit Tor Vergata University Hospital Rome Italy
-
- Sabina Cevoli
- Bologna Institute of Neurological Sciences, Scientific Institute for Research and Health Care Bologna Italy
-
- Piero Barbanti
- Headache and Pain Unit San Raffaele Pisana, Scientific Institute for Research and Health Care Rome Italy
抄録
<jats:title>Abstract</jats:title><jats:sec><jats:title>Background and purpose</jats:title><jats:p>A rapid response to preventive therapy is of pivotal importance in severely disabled patients with chronic migraine (CM) and diverse preventive treatment failures. This prospective, observational, multicenter real‐life study aimed at investigating the effectiveness of galcanezumab in the first 3 months of treatment of CM patients at 14 Italian headache centers.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>All consecutive adult patients with CM diagnosis with the clinical indication for galcanezumab were considered. We collected patients' baseline characteristics, monthly headache days, monthly painkiller intake, migraine clinical characteristics, and disability scale scores during a 1‐month run‐in period (baseline) and the first 3 months of therapy. Possible predictive factors of treatment were considered.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 156 patients (82.4% female, aged 47.3 ± 12.3 years) were enrolled. The 65 (41.7%) patients with a consecutive ≥50% response rate (RR) in the 3 months of therapy presented a lower body mass index (<jats:italic>p</jats:italic> = 0.004) and more frequently presented unilateral migraine pain (<jats:italic>p</jats:italic> = 0.002) and good response to triptans (<jats:italic>p</jats:italic> = 0.003). Persistent conversion from CM to episodic migraine was observed in 55.8% (87/156) of patients. They more frequently presented a good response to triptans (<jats:italic>p</jats:italic> = 0.003) and unilateral pain (<jats:italic>p</jats:italic> = 0.046). At baseline, 131 of 156 (83.9%) patients presented medication overuse (MO). Of these, 61.8% (81/131) no longer displayed MO consistently during the 3 months. These patients were more frequently responders to triptans (<jats:italic>p</jats:italic> = 0.002) and less frequently suffered from gastrointestinal comorbidity (<jats:italic>p</jats:italic> = 0.007).</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>Unilateral pain, good response to triptans, and normal weight may be associated with a persistent positive response in the first 3 months of therapy with galcanezumab in CM patients.</jats:p></jats:sec>
収録刊行物
-
- European Journal of Neurology
-
European Journal of Neurology 29 (4), 1198-1208, 2021-12-06
Wiley